Photocure completes enrolment in Phase IIb trial for the treatment of acne

Norwegian photodynamic technologies focused pharmaceutical company Photocure ASA (OSE: PHO) announced today it has completed patient enrolment in Phase IIb trial with Visonac for the treatment of moderate to severe acne vulgaris. A total of 150 dermatology practice and hospital patients between the ages of 12 and 35 have been enrolled over fifteen centres in the US. The patients will be treated for a six week period with results expected in Q3 2012.

Photocure expects that the data will support the design for a pivotal Phase III study in the US and Europe. Current treatment paradigm for patients suffering of moderate to severe acne is oral antibiotics or retinoids. Photocure feels that Visonac may satisfy a significant unmet medical need. Acne vulgaris (or cystic acne) is the single most common skin disease worldwide. Photocure’s stock is up around 5% going into last quarter of trading.